Document is current
Any future updates will be listed below
-
Authors
Harvey, Edward P.
Smith, Jeffrey S. https://orcid.org/0000-0003-2840-2899
Hurley, Joseph D. https://orcid.org/0000-0002-3903-318X
Granados, Alyana J.
Schmid, Ernst W. https://orcid.org/0000-0002-4662-5298
Liang-Lin, Jason G. https://orcid.org/0000-0003-4277-6694
Zhang, Huyang
Meara, Emily M. https://orcid.org/0009-0007-2643-8413
Wren, Elizabeth K.
Paul, Steffanie
Ferguson, Matthew P. https://orcid.org/0009-0004-9218-6283
Calvillo-Miranda, Victor G. https://orcid.org/0000-0001-8631-4622
Alcantar, Miguel A.
Marks, Debora S.
Walter, Johannes C. https://orcid.org/0000-0002-4186-7570
Kruse, Andrew C. https://orcid.org/0000-0002-1467-1222
Susa, Katherine J. https://orcid.org/0000-0003-0077-667X
- License Information
-
More Information
Article History
Received: 2 October 2025
Accepted: 3 April 2026
First Online: 23 April 2026
Competing interests
: E.P.H., J.S.S., J.D.H., K.J.S., and A.C.K. are co-inventors on a patent application for MRGPRX2 antagonist nanobodies. D.S.M. is an advisor for Dyno Therapeutics, Octant, Jura Bio, Tectonic Therapeutic, and Genentech, and is a co-founder of Seismic Therapeutic. J.C.W. is a co-founder of MOMA therapeutics, a company in which he has a financial interest. A.C.K. is a co-founder and consultant for biotechnology companies Tectonic Therapeutic and Seismic Therapeutic, and for the Institute for Protein Innovation, a non-profit research institute. J.S.S. is an advisor/investigator for Biogen. The remaining authors declare no competing interests.
